Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences, Inc. (NASDAQ: MRVI) is set to release its fourth quarter and full year 2022 financial results on February 22, 2023. The announcement will occur after the market closes, followed by a conference call at 2:00 p.m. PT/5:00 p.m. ET. Investors can join the call via telephone or through a live and archived webcast available on the company’s investor website. As a leading provider of life science reagents, Maravai supports research and development in drug therapies, diagnostics, and vaccines, catering to top biopharmaceutical and gene therapy firms.
Maravai LifeSciences has announced the appointment of William “Trey” Martin, III as President of its Biologics Safety Testing Segment starting December 5, 2022. He is expected to become the company’s CEO on July 27, 2023. Previously, Martin was placed on paid leave due to a lawsuit concerning a noncompetition agreement but has reached a confidential settlement. Christine Dolan will continue as COO reporting to Martin, while Carl Hull remains Executive Chairman and Interim CEO. The company emphasizes confidence in Martin’s leadership amidst these transitions.
Summary not available.
Maravai LifeSciences (NASDAQ: MRVI) announced the launch of the MockV® RVLP Kit through its subsidiary, Cygnus Technologies. This innovative kit allows biopharmaceutical scientists to quantify the removal of Retrovirus-Like Particles (RVLPs) from CHO cell lines, crucial for ensuring viral safety in biopharmaceutical production. The kit includes a concentrated stock solution of RVLPs and addresses industry needs for viral clearance studies, enabling companies to optimize manufacturing processes independently. This launch marks the second product in the MockV® portfolio since acquiring MockV Solutions in 2020.
Maravai LifeSciences (NASDAQ: MRVI) announces participation in two key investor conferences. On November 8, 2022, CFO Kevin Herde and COO Brian Neel will engage in a fireside chat at the Credit Suisse Healthcare Conference in California. Subsequently, on December 6, 2022, Mr. Herde will present at the Nasdaq Investor Conference in London, UK. Live webcasts will be accessible via their Investor Relations website, with archived versions available post-event. Maravai is a key provider of life science reagents supporting drug therapy and diagnostics development.
Maravai LifeSciences Holdings, Inc. (MRVI) reported Q3 2022 revenue of $191.3 million, down 7% year-over-year, driven by a 4% decline in Nucleic Acid Production revenue. Net income reached $99.7 million, while Adjusted EBITDA was $132.5 million. The company has updated its 2022 financial guidance, reflecting expectations amidst ongoing market conditions. The revenue included $126.5 million from COVID-19 related CleanCap sales, which decreased from the previous year due to lower demand from vaccine manufacturers.
Maravai LifeSciences faces a legal challenge as its newly appointed CEO, Trey Martin, is accused of breaching a noncompetition agreement by three subsidiaries of Danaher Corporation. The Delaware Court of Chancery has issued a temporary restraining order against Martin, preventing him from working at Maravai until a preliminary injunction hearing. In the interim, former CEO Carl Hull has been reinstated to lead the company. Hull expressed confidence in Martin and criticized the lawsuit's impact on employee mobility in California.
Maravai LifeSciences, Inc. (NASDAQ: MRVI) will announce its third quarter 2022 financial and operational results on November 2, 2022, after market close. The company will also host a conference call at 2:00 PM PT/5:00 PM ET on the same day. Maravai specializes in critical life science products that support drug therapy development, diagnostics, and vaccine innovation. Their solutions are vital for research in human diseases and serve leading biopharmaceutical and gene therapy firms.
Maravai LifeSciences (NASDAQ: MRVI) announced the appointment of William “Trey” Martin, III as its new CEO, succeeding co-founder Carl Hull, who transitions to Executive Chairman. Martin brings over 25 years of leadership experience in life sciences, particularly in genomic medicine from Danaher Corporation. Hull will continue guiding Maravai’s long-term strategy alongside Martin. The management change aims to leverage Martin's expertise in driving growth within nucleic acid synthesis and biologics testing. The upcoming earnings call on November 2, 2022, will further discuss this transition.
Maravai (NASDAQ: MRVI) announced the addition of GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate to its product line through its subsidiary TriLink BioTechnologies. This critical raw material enhances mRNA manufacturing, supporting researchers in accelerating drug discovery timelines while sourcing materials domestically. The demand for N1-Methyl-Pseudouridine has surged, particularly due to its role in FDA-approved mRNA vaccines. TriLink aims to strengthen its industry position by leveraging over ten years of experience in manufacturing this product.